Propel Bio Management
Propel Bio Management reported 30 stocks worth $189M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are PAGP (17.5%), ACHV (16.6%) and DCTH (5.1%). Compared with Q2 2026, the fund opened new positions in COLL, CABA and PROK, added to MIST, PHAT and MAZE, trimmed ACHV, DCTH and CORT and sold out of ZVRA, EYPT and SLN.
Latest filing: what Propel Bio Management did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() PAGP Plains GP Hldgs L P | $33M | 17.5% | 1.3M | No change | 8 of 8 | |
| 2 | ![]() ACHV Achieve Life Sciences Inc | $31.3M | 16.6% | 3.9M | −170K (−4%) | 8 of 8 | |
| 3 | ![]() DCTH Delcath Sys Inc | $9.7M | 5.1% | 605K | −267K (−31%) | 8 of 8 | |
| 4 | ![]() COLL Collegium Pharmaceutical Inc | $9M | 4.8% | 410K | New position | 1 of 8 | |
| 5 | ![]() CORT Corcept Therapeutics Inc | $8.7M | 4.6% | 75K | −61K (−45%) | 3 of 8 | |
| 6 | ![]() AQST Aquestive Therapeutics Inc | $8.6M | 4.6% | 279K | −1.2M (−81%) | 3 of 8 | |
| 7 | ![]() MIST Milestone Pharmaceuticals in | $8.2M | 4.3% | 9.4M | +2M (+27%) | 7 of 8 | |
| 8 | ![]() PHAT Phathom Pharmaceuticals Inc | $8.1M | 4.3% | 1.1M | +56K (+5%) | 8 of 8 | |
| 9 | ![]() CMPS Compass Pathways PLC | $6.8M | 3.6% | 549K | −24K (−4%) | 6 of 8 | |
| 10 | ![]() OBIO Orchestra Biomed Hldgs Inc | $5.6M | 3.0% | 897K | No change | 3 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 13, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Propel Bio Management 13F FAQ
What does Propel Bio Management own?
Propel Bio Management reported 30 stocks worth $189M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are PAGP (17.5%), ACHV (16.6%) and DCTH (5.1%). The table above lists every position in the filing (the top 10 without an account).
What did Propel Bio Management buy and sell in Q3 2026?
Compared with Q2 2026: 5 new positions, 5 added to, 15 trimmed and 4 sold out. New positions include COLL, CABA and PROK. It sold all of ZVRA, EYPT and SLN.
When will Propel Bio Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Propel Bio Management's portfolio worth?
The Q3 2026 filing reports $189M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.





















